Published: 2021-05-26

Assessment of serum prolactin level in hepatic encephalopathy patient

Richa Giri, Saksham Pandey, J. S. Kushwaha


Background: Hepatic encephalopathy (HE) is a complex neuropsychiatric disorder that arises in both acute and chronic liver disease. It is typified by the disturbance in consciousness and behavior, personality changes fluctuating neurological signs, asterisks or flapping tremors and distinctive EEG changes. This study was established to assess and evaluate the serum prolactin level in hepatic encephalopathy (HE) patient.

Methods: The present cross-sectional study consisted a total 70 patients, out of those 35 were having HE and the rest 35 had no clinical evidence of HE. Those patients without clinical evidence of HE but having cirrhosis of liver, acute viral hepatitis and normal healthy controls.

Results: Serum prolactin levels of patients of cirrhosis of liver with hepatic encephalopathy ranged from 37.6-210.7 ng/ml with a mean of 73.63±43.85 ng/ml. In patients, Prolactin levels were found significantly high in cirrhosis of liver patients with HE then cirrhosis of liver without HE patients (p<0.001). Level of serum prolactin in patients with hepatic encephalopathy with Fulminant hepatic failure (FHF) ranged from 30.6-119.7 ng/ml with a mean of 71.24±26.87 ng/ml. The values obtained from these are significantly higher as compared to those in normal healthy controls and those in acute viral hepatitis (p<0.001). Level of serum prolactin in patients of liver cirrhosis without hepatic encephalopathy ranged from 18.6-26.4 ng/ml with a mean of 21.48±2.43 ng/ml. These values are significantly higher than those found in normal healthy controls and those found in acute viral hepatitis (p<0.001). Mortality rate was 70% in patients of cirrhosis of liver with HE.

Conclusions: Serum prolactin levels (SPL) are significantly higher in patients with complications such as hepatic encephalopathy and higher the levels, greater the severity. Hence, we conclude that level of serum prolactin can be used as a useful prognostic marker in patients with cirrhosis of the liver as well as an early indicator of its complications.


Hepatic encephalopathy, Serum prolactin, Liver cirrhosis, Acute viral hepatitis, Fulminant hepatic failure

Full Text:



Butterworth RF. Neurosteroids in hepatic encephalopathy: Novel insights and new therapeutic opportunities, J Steroid Biochem Mol Biol. 2016:160:94-7.

American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61:642‑59.

Jha SK, Kannan S. Serum prolactin in patients with liver disease in comparison with healthy adults: A preliminary cross-sectional study. Int J App Basic Med Res. 2016;6:8-10.

Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nature Reviews Gastroenterol Hepatol. 2010;7(9):515-25.

Poordad FF. Review article: the burden of hepatic encephalopathy. Alimentary Pharmacol Therap. 2007;25(1):3-9.

Romero-Gómez M, Boza F, García-Valdecasas MS, García E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001;96(9):2718-23.

Häussinger D. Hepatic encephalopathy. Acta Gastro-Enterologica Belgica. 2010;73(4):457-64.

Felipo V, Urios A, Montesinos E, Molina I, Garcia-Torres M L, Civera M et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metabolic Brain Dis. 2012;27(1):51-8.

Felipo V, Butterworth RF. Neurobiology of ammonia. Progress Neurobiol. 2002;67(4):259-79.

Abbott NJ, Ronnb L, Hansson E. Astrocyte- endothelial interactions at the blood-brain barrier. Nature Reviews Neuroscience. 2006;7(1):41-53.

Butterworth RF, Giguere JF, Michaud J, Lavoie JG, Layrargues P. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochemical Pathol. 1987;6(1):1-12.

Butterworth RF, Girard G, Giguere JF. Regional differences in the capacity for ammonia removal by brain following portocaval anastomosis. J Neurochem. 1988;51(2):486-90.

Corenblum B, Shaffer EA. Hyperprolactinemia in hepatic encephalopathy may result from impaired central dopaminergic neurotransmission. Horm Metab Res. 1989;21:675‑7.

Koller T, Kollerová J, Huorka M, Hlavatý T, Payer J. Impact of basal prolactin levels on the prevalence of complications and the prognosis of patients with liver cirrhosis. Vnitr Lek. 2009;55:468‑73.

Balakrishnan CH, Rajeev H. Correlation of Serum Prolactin Level to Child Pugh Scoring System in Cirrhosis of Liver. J Clin Diagnostic Res. 2017;11(7):OC30-3.

Velissaris D, Karanikolas M, Kalogeropoulos A, Solomou E, Polychronopoulos P, Thomopoulos K et al. Pituitary hormone circadian rhythm alterations in cirrhosis patients with subclinical hepatic encephalopathy. World J Gastroenterol. 2008;14:4190‑5.

Gibbs DM, Neill JD. Dopamine levels in hypophysial stalk blood are saffcimt to inhibit prolactin secretion in vivo. Endocrinology. 1978;102(6):1895-900.

McClain CJ, Kromhout JP, Elson MK, Van Thiel DH. Hyperprolactinemia in portal systemic encephalopathy. Dig Dis Sci. 1981;26:353‑7.

Sharma MP, Acharya SK, Karmarkar MG. Significance of prolactin levels in protosystemic encephalopathy. J Assoc Physicians India. 1988;36:207‑9.

Mukherjee S, Kar M, Dutta S. Observation on serum prolactin in hepatic cirrhosis. J Indian Med Assoc 1991;89:307‑8.